Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Neurofibromatosis 2 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Medulloblastoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × Vascular Endothelial Growth Factor A × Clear all
NCT00483834 2019-02-15

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

University Health Network, Toronto

Phase 2 Completed
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡